Company news

Myriad Genetics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics

October 2, 2024

Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

September 30, 2024

Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference

September 17, 2024

Myriad Genetics to Host Investor Event on October 9, 2024

September 4, 2024

Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

August 20, 2024

Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

August 5, 2024

Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific

July 31, 2024

Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer

July 30, 2024

Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024

July 29, 2024

What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk

July 16, 2024

Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing

July 10, 2024

Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

July 8, 2024

Myriad Genetics Earns 2024 Great Place To Work® Certification™

July 1, 2024

Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries

June 10, 2024

Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen

June 3, 2024

Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool

June 2, 2024

QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications

May 29, 2024

Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting

May 22, 2024

New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer

May 15, 2024

Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA

May 6, 2024

Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business

May 6, 2024

Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024

April 29, 2024

Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor

April 16, 2024

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen

April 15, 2024

Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

April 8, 2024

Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

March 20, 2024

Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device

March 19, 2024

Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in t...

February 26, 2024

Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

February 26, 2024

Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

February 20, 2024

Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

February 14, 2024

Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

January 31, 2024

Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology

January 29, 2024

Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

January 17, 2024

Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO

January 8, 2024

Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance

December 20, 2023

Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care

December 19, 2023

Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents

November 19, 2023

Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers

November 15, 2023

Myriad Genetics to Participate in Stephens Annual Investment Conference

November 8, 2023

Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock

November 7, 2023

Myriad Genetics Announces Pricing of Upsized Offering of Common Stock

November 7, 2023

Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance

November 5, 2023

Myriad Genetics Appoints Sam Raha as Chief Operating Officer

October 31, 2023

Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023

October 30, 2023

QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer

October 25, 2023

New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood

September 27, 2023

Breast cancer awareness month: new cancer risk survey reveals risk factors are widely misunderstood

September 27, 2023

Myriad Genetics Issues 2022 Environmental, Social and Governance Report

September 18, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 48 decks. Every deck is listed under its year.